Literature DB >> 23780638

Patterns of consultation and treatment of patients with hepatocellular carcinoma presenting to a large academic medical center in the US.

Sylvie Stacy1, Omar Hyder, David Cosgrove, Joseph M Herman, Ihab Kamel, Jean-Francois H Geschwind, Ahmet Gurakar, Robert Anders, Andrew Cameron, Timothy M Pawlik.   

Abstract

BACKGROUND: Management of hepatocellular carcinoma (HCC) often involves many subspecialist providers, as well as a broad range of treatment options. This study sought to evaluate referral and treatment patterns among patients with HCC at a large academic medical center.
METHODS: Data from our cancer registry between 2003-2011 were abstracted on 394 patients who were primarily diagnosed/treated for HCC at Johns Hopkins Hospital (JHH); data on patients who were diagnosed/treated with HCC elsewhere and who received secondary treatment at JHH (n = 391) were also abstracted for comparison purposes.
RESULTS: Among the main cohort, the most common specialties to be consulted were surgery (n = 225, 57.1%), gastroenterology (n = 225, 57.1%), and interventional radiologist (n = 206, 52.3%), while only 96 (24.4%) were referred to medical oncology. Factors associated with surgical consultation included younger age (odds ratio (OR) 3.35, 95% CI 1.62-6.92), tumor size <5 cm (OR 1.82, 1.09-3.02), and unilobar disease (OR 2.94, 1.31-6.59) (all P < 0.05). Patients initially diagnosed/treated elsewhere had larger tumors (4 vs. 6 cm), bilateral disease (19.2 vs. 26.8%), and were more likely to be seen by interventional radiology (all P < 0.05)
CONCLUSIONS: Most patients were seen by surgeons, gastroenterologists, or interventional radiologists, with only a minority being seen by medical oncologists. Referral patterns depended on patient-level factors, as well as extent of disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23780638      PMCID: PMC4002207          DOI: 10.1007/s11605-013-2253-y

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  27 in total

Review 1.  Prognostic prediction and treatment strategy in hepatocellular carcinoma.

Authors:  Jordi Bruix; Josep M Llovet
Journal:  Hepatology       Date:  2002-03       Impact factor: 17.425

2.  Referrals of adult patients from primary care: demographic disparities and their relationship to HMO insurance.

Authors:  P Franks; C M Clancy
Journal:  J Fam Pract       Date:  1997-07       Impact factor: 0.493

3.  The American Heart Association's recommendations for expanding the applications of existing and future clinical registries: a policy statement from the American Heart Association.

Authors:  Vincent J Bufalino; Frederick A Masoudi; Steven K Stranne; Katie Horton; Nancy M Albert; Craig Beam; Robert O Bonow; Roger L Vern Davenport; Meighan Girgus; Gregg C Fonarow; Harlan M Krumholz; Mark W Legnini; William R Lewis; Graham Nichol; Eric D Peterson; John S Rumsfeld; Lee H Schwamm; David M Shahian; John A Spertus; Pamela K Woodard; Clyde W Yancy
Journal:  Circulation       Date:  2011-04-11       Impact factor: 29.690

Review 4.  Determining who should be referred for total hip and knee replacements.

Authors:  Lisa A Mandl
Journal:  Nat Rev Rheumatol       Date:  2013-03-12       Impact factor: 20.543

5.  Understanding surgical decision making in early hepatocellular carcinoma.

Authors:  Hari Nathan; John F P Bridges; Richard D Schulick; Andrew M Cameron; Kenzo Hirose; Barish H Edil; Christopher L Wolfgang; Dorry L Segev; Michael A Choti; Timothy M Pawlik
Journal:  J Clin Oncol       Date:  2011-01-04       Impact factor: 44.544

6.  Racial disparities in the use of palliative therapy for ureteral obstruction among elderly patients with advanced prostate cancer.

Authors:  Benjamin A Spencer; Beverly J Insel; Dawn L Hershman; Mitchell C Benson; Alfred I Neugut
Journal:  Support Care Cancer       Date:  2013-01-06       Impact factor: 3.603

7.  The National Cancer Data Base Report on treatment patterns for hepatocellular carcinomas: improved survival of surgically resected patients, 1985-1996.

Authors:  W G Cance; A K Stewart; H R Menck
Journal:  Cancer       Date:  2000-02-15       Impact factor: 6.860

8.  Underutilization of therapy for hepatocellular carcinoma in the medicare population.

Authors:  Shimul A Shah; Jillian K Smith; Youfu Li; Sing Chau Ng; James E Carroll; Jennifer F Tseng
Journal:  Cancer       Date:  2010-10-13       Impact factor: 6.860

9.  Impact of a single-day multidisciplinary clinic on the management of patients with liver tumours.

Authors:  J Zhang; M N Mavros; D Cosgrove; K Hirose; J M Herman; S Smallwood-Massey; I Kamel; A Gurakar; R Anders; A Cameron; J F H Geschwind; T M Pawlik
Journal:  Curr Oncol       Date:  2013-04       Impact factor: 3.677

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  7 in total

1.  Temporal trends in population-based death rates associated with chronic liver disease and liver cancer in the United States over the last 30 years.

Authors:  Yuhree Kim; Aslam Ejaz; Amit Tayal; Gaya Spolverato; John F P Bridges; Robert A Anders; Timothy M Pawlik
Journal:  Cancer       Date:  2014-06-10       Impact factor: 6.860

2.  Development, Practice Patterns, and Early Clinical Outcomes of a Multidisciplinary Liver Cancer Clinic.

Authors:  Angela Y Jia; Aleksandra Popovic; Aditya A Mohan; Jane Zorzi; Paige Griffith; Amy K Kim; Robert A Anders; Richard A Burkhart; Kelly Lafaro; Christos Georgiades; Nilofer S Azad; Robert P Liddell; Marina Baretti; Ihab R Kamel; Amol Narang; Mark Yarchoan; Jeffrey Meyer
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

3.  LINC00491 promotes cell growth and metastasis through miR-324-5p/ROCK1 in liver cancer.

Authors:  Wei Wang; Tao Yang; Dongsheng Li; Yinpeng Huang; Guang Bai; Qing Li
Journal:  J Transl Med       Date:  2021-12-07       Impact factor: 5.531

4.  Upregulated lncRNA-UCA1 contributes to progression of hepatocellular carcinoma through inhibition of miR-216b and activation of FGFR1/ERK signaling pathway.

Authors:  Feng Wang; Hou-Qun Ying; Bang-Shun He; Yu-Qin Pan; Qi-Wen Deng; Hui-Ling Sun; Jie Chen; Xian Liu; Shu-Kui Wang
Journal:  Oncotarget       Date:  2015-04-10

5.  Long non-coding RNA SPRY4-IT1 promotes development of hepatic cellular carcinoma by interacting with ERRα and predicts poor prognosis.

Authors:  Guifang Yu; Jieheng Lin; Chengcheng Liu; Kailian Hou; Min Liang; Boyun Shi
Journal:  Sci Rep       Date:  2017-12-07       Impact factor: 4.379

6.  Silence of Stomatin-Like Protein 2 Represses Migration and Invasion Ability of Human Liver Cancer Cells via Inhibiting the Nuclear Factor Kappa B (NF-κB) Pathway.

Authors:  Wenyu Zhu; Wei Li; Qian Geng; Xiaoying Wang; Wei Sun; Hua Jiang; Xiaolin Pu
Journal:  Med Sci Monit       Date:  2018-10-25

7.  Therapeutic Efficacy of Delta-Like Ligand 4 Gene Vaccine Overexpression on Liver Cancer in Mice.

Authors:  Yi Yu; Yang Zhao; Guangming Zhou; Xiang Wang
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.